These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 20428102)

  • 1. International trends in erythropoietin use and hemoglobin levels in hemodialysis patients.
    McFarlane PA; Pisoni RL; Eichleay MA; Wald R; Port FK; Mendelssohn D
    Kidney Int; 2010 Jul; 78(2):215-23. PubMed ID: 20428102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. International Comparisons to Assess Effects of Payment and Regulatory Changes in the United States on Anemia Practice in Patients on Hemodialysis: The Dialysis Outcomes and Practice Patterns Study.
    Fuller DS; Bieber BA; Pisoni RL; Li Y; Morgenstern H; Akizawa T; Jacobson SH; Locatelli F; Port FK; Robinson BM
    J Am Soc Nephrol; 2016 Jul; 27(7):2205-15. PubMed ID: 26582402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perihospitalization patterns of hemoglobin levels and erythropoiesis-stimulating agent doses in US hemodialysis patients, 1998-2009.
    Foley RN; Solid CA; Lamb K
    Hemodial Int; 2014 Jan; 18(1):24-31. PubMed ID: 24131588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in dialysis treatment modalities during institution of flat rate reimbursement and quality assurance programs.
    Kleophas W; Karaboyas A; Li Y; Bommer J; Reichel H; Walter A; Icks A; Rump LC; Pisoni RL; Robinson BM; Port FK
    Kidney Int; 2013 Sep; 84(3):578-84. PubMed ID: 23636176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anemia management under a bundled payment policy for dialysis: a preview for the United States from Japan.
    Wish JB
    Kidney Int; 2011 Feb; 79(3):265-7. PubMed ID: 21228798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in anemia management and hemoglobin levels following revision of a bundling policy to incorporate recombinant human erythropoietin.
    Hasegawa T; Bragg-Gresham JL; Pisoni RL; Robinson BM; Fukuhara S; Akiba T; Saito A; Kurokawa K; Akizawa T
    Kidney Int; 2011 Feb; 79(3):340-6. PubMed ID: 20962740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of facility-level hemoglobin concentration on dialysis patient risk of transfusion.
    Collins AJ; Monda KL; Molony JT; Li S; Gilbertson DT; Bradbury BD
    Am J Kidney Dis; 2014 Jun; 63(6):997-1006. PubMed ID: 24315770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exceeding hemoglobin target levels in US hemodialysis patients receiving epoetin, 1999 to 2002.
    Foley RN; Zhang R; Gilbertson DT; Dunning S; Ishani A; Collins AJ
    Hemodial Int; 2007 Jul; 11(3):333-9. PubMed ID: 17576299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomedical system dynamics to improve anemia control with darbepoetin alfa in long-term hemodialysis patients.
    McCarthy JT; Hocum CL; Albright RC; Rogers J; Gallaher EJ; Steensma DP; Gudgell SF; Bergstralh EJ; Dillon JC; Hickson LJ; Williams AW; Dingli D
    Mayo Clin Proc; 2014 Jan; 89(1):87-94. PubMed ID: 24388026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The DOPPS Practice Monitor for US dialysis care: trends through August 2011.
    Pisoni RL; Fuller DS; Bieber BA; Gillespie BW; Robinson BM
    Am J Kidney Dis; 2012 Jul; 60(1):160-5. PubMed ID: 22560744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the Handling Erythropoietin Resistance With Oxpentifylline (HERO) trial.
    Johnson DW; Pascoe EM; Badve SV; Dalziel K; Cass A; Clarke P; Ferrari P; McDonald SP; Morrish AT; Pedagogos E; Perkovic V; Reidlinger D; Scaria A; Walker R; Vergara LA; Hawley CM;
    Am J Kidney Dis; 2015 Jan; 65(1):49-57. PubMed ID: 25115616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients.
    Regidor DL; Kopple JD; Kovesdy CP; Kilpatrick RD; McAllister CJ; Aronovitz J; Greenland S; Kalantar-Zadeh K
    J Am Soc Nephrol; 2006 Apr; 17(4):1181-91. PubMed ID: 16565261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erythropoiesis-stimulating agent responsiveness and mortality in hemodialysis patients: results from a cohort study from the dialysis registry in Japan.
    Fukuma S; Yamaguchi T; Hashimoto S; Nakai S; Iseki K; Tsubakihara Y; Fukuhara S
    Am J Kidney Dis; 2012 Jan; 59(1):108-16. PubMed ID: 21890255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anemia Management in the China Dialysis Outcomes and Practice Patterns Study.
    Zuo L; Wang M; Hou F; Yan Y; Chen N; Qian J; Wang M; Bieber B; Pisoni RL; Robinson BM; Anand S
    Blood Purif; 2016; 42(1):33-43. PubMed ID: 27045519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monthly continuous erythropoietin receptor activator treatment maintains stable hemoglobin levels in routine clinical management of hemodialysis patients.
    Weinreich T; Leistikow F; Hartmann HG; Vollgraf G; Dellanna F;
    Hemodial Int; 2012 Jan; 16(1):11-9. PubMed ID: 22098689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of anemia in erythropoietin-treated pediatric as compared to adult chronic dialysis patients.
    Chavers BM; Roberts TL; Herzog CA; Collins AJ; St Peter WL
    Kidney Int; 2004 Jan; 65(1):266-73. PubMed ID: 14675059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of a change in erythropoiesis-stimulating agent dose during hospitalization and subsequent hemoglobin levels and transfusions in hemodialysis patients.
    Wong BC; Ravani P; Manns BJ; Lewin A; Zhang X; Chin R; Hemmelgarn BR; Tonelli M; Oliver MJ; Quinn RR
    Am J Kidney Dis; 2013 Nov; 62(5):947-52. PubMed ID: 23856380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epoetin alfa use in patients with ESRD: an analysis of recent US prescribing patterns and hemoglobin outcomes.
    Collins AJ; Brenner RM; Ofman JJ; Chi EM; Stuccio-White N; Krishnan M; Solid C; Ofsthun NJ; Lazarus JM
    Am J Kidney Dis; 2005 Sep; 46(3):481-8. PubMed ID: 16129210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Higher doses of erythropoietin-stimulating agents and hyporesponsiveness to their effects are associated with increased mortality among prevalent hemodialysis patients.
    Nishio A; Chhatkuli BP; Ma JZ; Kalantari K
    Blood Purif; 2013; 36(1):29-36. PubMed ID: 23735569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.